Navigation Links
Six Presentations on Tocagen's Toca 511 to be Given at the Society of Neuro-Oncology Annual Meeting
Date:11/22/2013

time MRI-guided delivery for evaluation of safety and efficacy,"  Friday Nov. 22, 7 to 9 p.m. PST
  • "Intravenous administration of Toca 511 results in uniform distribution of viral spread within the tumor and increased survival in a synergistic, orthotopic mouse glioma model," Saturday Nov. 23, 5 to 7 p.m. PST
  • "Toca 511 gene transfer in combination with temozolomide appears safe and demonstrates synergistic therapeutic efficacy in mouse glioblastoma model," Saturday Nov. 23, 5 to 7 p.m. PST
  • "Prodrug activator gene therapy with a non-lytic retroviral replicating vector (Toca 511) radiosensitizes glioma cells after intracellular generation of 5-fluorouracil," Saturday, Nov. 23, 5 to 7 p.m. PST
  • "Enhancing retroviral replicating vector-mediated prodrug activator gene therapy with engineered mesenchymal stem cells in animal models of glioma," Saturday Nov. 23, 5 to 7 p.m. PST
  • About Toca 511 & Toca FC

    The combination of Toca 511 (vocimagene amiretrorepvec) for injection and Toca FC (flucytosine) extended-release tablets, is being investigated in Phase I studies at leading centers across the US in clinical studies in patients with recurrent high grade glioma, including GBM. Toca 511 is a retroviral replicating vector (RRV) that is designed to deliver a prodrug activator gene called cytosine deaminase (CD) selectively to cancer cells. After allowing time for Toca 511 to spread through the tumor, those cancer cells expressing the CD gene can convert the antibiotic drug flucytosine into the anti-cancer drug 5-fluorouracil (5-FU). By producing 5-FU locally, this technology has the potential to produce much higher intratumoral concentrations of 5-FU than can be attained with systemic administration.  In these studies, patients receive a single administration of Toca 511 at the time of surgery (craniotomy or transcranial) followed by repeat cycles of oral Toca FC. To date, a total of 57 patients have receiv
    '/>"/>

    SOURCE Tocagen Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. Cyberonics To Webcast Presentations From Companys Investor And Analyst Meeting
    2. Star Scientific Files Third-Quarter Financials for 2013; Comments on Companys Corporate Leadership Transition, Roskamp Institute Scientific Presentations at 2013 Annual Society for Neuroscience Convention
    3. Orexigen and Takeda Announce Multiple Contrave Data Presentations at the ObesityWeek Meeting in Atlanta
    4. ViroPharma Announces Upcoming Data Presentations at the 2013 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting
    5. Thoratec Announces Presentations At Investor Conferences For November 2013
    6. Boston Scientific Announces Schedule Of Major Presentations At Transcatheter Cardiovascular Therapeutics 2013
    7. Volcano Announces Upcoming Data Presentations from Large-Scale Studies on Physiology and Imaging Technologies at TCT 2013
    8. Medac Pharma, Inc. Announces Multiple Poster Presentations During the 2013 ACR/ARHP Annual Meeting
    9. Diabetes Alliance to Feature 17 Presentations for Linagliptin and Investigational Compound Empagliflozin^ During the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD)
    10. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
    11. CTI Announces Data Presentations at the 18th Congress of the European Hematology Association
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
    (Date:1/15/2014)... 2014  A novel wearable injector slightly larger than an Oreo ... to self-inject prescription drugs in the large doses required to ... autoimmune deficiencies, and genetic disorders.  An emerging ... 2018, according to analysts.   Many of these drugs will require ...
    (Date:1/14/2014)... Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company of GMH ... Medical Equipment, Inc. ("Progressive") of Clarion, PA ... were not disclosed. Progressive is a full ... of sleep, mobility, and respiratory products to customers in the ...
    Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
    ... 2011 /PRNewswire-Asia-FirstCall/ -- Concord Medical Services Holdings Limited ("Concord ... largest network of radiotherapy and diagnostic imaging centers in ... financial results for the fourth quarter and fiscal year ... on March 28, 2011. Concord Medical,s management will hold ...
    ... 17, 2011 Pharmaceutics International Inc. (Pii), a ... the appointment of Rampurna Prasad Gullapalli as vice ... responsible for providing strategic scientific and technical leadership ... novel drug delivery technologies for Pii,s contract development ...
    Cached Medicine Technology:Concord Medical to Report Fourth Quarter and Fiscal Year 2010 Financial Results on Monday, March 28, 2011 2Pharmaceutics International Inc. (Pii) Announces Appointment of Rampurna Prasad Gullapalli, Ph.D. as Vice President of Drug Delivery Technologies 2
    (Date:4/18/2014)... have been awarded two-year grants for their work on ... Of the 110 initial submissions to the new Novo ... four projects were funded, three of which are led ... Ph.D.; G. William Wong, Ph.D.; and Elias Zambidis, M.D., ... will use his $500,000 proof of principle grant to ...
    (Date:4/18/2014)... . A ... A team led by Ludwik Leibler from the Laboratoire ... Letourneur from the Laboratoire Recherche Vasculaire Translationnelle (INSERM/Universits Paris ... principle of adhesion by aqueous solutions of nanoparticles can ... tissues. This easy-to-use gluing method has been tested on ...
    (Date:4/17/2014)... have identified new pain relief targets that could ... BBSRC-funded researchers at King,s College London made the ... in the periphery of the body. , Dr ... identifying mechanisms underlying pain generation and our findings ... side effects." , One potential side effect of ...
    (Date:4/17/2014)... Colo. (April 17, 2014) Two recent papers ... researcher and colleagues may help scientists develop treatments ... Yellow fever, Japanese encephalitis and other disease-causing flaviviruses. ... biochemistry and molecular genetics at the School of ... Howard Hughes Medical Institute, and colleagues recently published ...
    (Date:4/17/2014)... (April 17, 2014) Doctors who treat patients ... lymphangioleiomyomatosis (LAM) can face an agonizing treatment decision. ... the disease and help relieve shortness of breath. ... and sirolimus can cause potentially fatal complications following ... Dr. Daniel Dilling, medical director of Loyola University ...
    Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
    ... Newest and Largest Hope Lodge in,New York City, NEW ... challenges. Finding an affordable, supportive place to stay,during treatment shouldn,t ... and largest Hope Lodge in the nation: the Hope Lodge,New ... steps from Penn Station at 132 W. 32 St., the ...
    ... Compendium Helps to Assure the Safety and Purity ... ... Pharmacopeia (USP),today announced the release of the latest edition of the ... quality and,purity of ingredients found in foods consumed by the public ...
    ... a five-year, $20.5 million grant from the Bill & ... the biological factors underlying immune system control of HIV, ... support to the International HIV Controllers Study, which currently ... has the overall goal of discovering information that can ...
    ... Needs, WASHINGTON, March 4 To meet increased ... from,the Global War on Terror, the Department of Veterans ... "Not all the wounds of war are visible," said ... committed to ensuring veterans receive,world-class care for mental health ...
    ... a significant improvement in their quality of life, ... research published in the March 2008 issue of ... German study evaluated the quality of life of ... Implant Questionnaire (NCIQ), a self-administered assessment that asks ...
    ... of genetic material between two closely related strains of ... and 1951 human flu epidemics, according to biologists. The ... pandemics and others lead to seasonal epidemics., Until now, it ... viruses swap genes with influenza viruses that infect birds ...
    Cached Medicine News:Health News:American Cancer Society to Open Doors to Its New Free Lodging and Support Center in NYC for Cancer Patients and Caregivers 2Health News:U.S. Pharmacopeia Releases New Edition of the Food Chemicals Codex 2Health News:Mass. General Hospital receives Gates Foundation grant to expand HIV controllers study 2Health News:Mass. General Hospital receives Gates Foundation grant to expand HIV controllers study 3Health News:VA to Train More Psychologists 2Health News:Study uncovers cause of flu epidemics 2Health News:Study uncovers cause of flu epidemics 3
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    Medicine Products: